Anti-Hepatitis B Virus Activity of ORI-9020, a Novel Phosphorothioate Dinucleotide, in a Transgenic Mouse Model
Open Access
- 1 June 2004
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (6) , 2318-2320
- https://doi.org/10.1128/aac.48.6.2318-2320.2004
Abstract
ORI-9020, a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA ( P ≤ 0.001). Levels of HBeAg and HBsAg in serum and of HBcAg in liver were not affected by treatment. A minimal effective dosage was determined to be between 1.6 and 0.5 mg/kg of body weight/day, which was similar to that observed for adefovir dipivoxil.Keywords
This publication has 5 references indexed in Scilit:
- Phosphorothioate Di- and Trinucleotides as a Novel Class of Anti-Hepatitis B Virus AgentsAntimicrobial Agents and Chemotherapy, 2004
- Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virusAntiviral Research, 2003
- Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virusAntiviral Research, 2002
- Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudineAntiviral Research, 1999
- Transgenic mice as a chemotherapeutic model for hepatitis B virus infection.1998